POST Online Media Lite Edition



 

NEWLY REPORTED COVID-19 CASES (11.19.2021, 4:50pm CEST, WHO):   India 11,106    Brazil 11,977    United Kingdom 46,858    Russia 37,156    Turkey 22,234    France 19,840    Argentina 1,553    Germany 52,970    Spain 3,932    Columbia 2,257    Italy 10,645    Mexico 3,836    Ukraine 20,050    Poland 23,242    Philippines 1,297    Malaysia 6,380    Netherlands 23,680    Peru 1,370    Thailand 6,855    Czechia 13,374    Canada 2,448    Romania 3,076    Chile 2,611    Serbia 3,219    Sweden 1,210    Portugal 2,398    Vietnam 10,223    Kazakhstan 1,272    Austria 14,212    Hungary 11,289    Greece 7,276    Georgia 4,278    Bulgaria 2,785    Belarus 1,844    Slovakia 7,418    Azerbaijan 2,124    Croatia 7,270    Bolivia 1,119    Ireland 4,646    Lithuania 1,847    Denmark 4,013    South Korea 3,034    Slovenia 3,662    Latvia 1,221    Laos 1,401    China 31    New Zealand 200    Australia 1,302   

Candidate Ebola vaccine still effective when highly diluted

Christian Fernsby |
A single dose of a highly diluted VSV-Ebola virus (EBOV) vaccine approximately one-millionth of what is in the vaccine being used to help control the ongoing Ebola outbreak in the Democratic Republic of the Congo (DRC) remains fully protective against disease in experimentally infected monkeys, according to National Institutes of Health scientists.

Article continues below




The NIH investigators completed the vaccine dosage study using cynomolgus macaques and an updated vaccine component to match the EBOV Makona strain that circulated in West Africa from 2014-16.

The study appears in Lancet's EBioMedicine.

Nearly 250,000 people have received the investigational VSV-EBOV vaccine since August 2018 as part of a "ring vaccination" program to help stem the outbreak.

The vaccine appears to be safe and highly effective.

The manufacturer has announced that it has submitted a biologics license application to the U.S. Food and Drug Administration.

VSV-EBOV is based on a live-attenuated vesicular stomatitis virus and delivers an EBOV protein to elicit protective immune responses.

With the continued need to vaccinate individuals in the DRC and surrounding countries, a potential shortage of VSV-EBOV vaccine is a concern and further dose adjustment is a possible solution.

Scientists from NIH's Rocky Mountain Laboratories (RML), part of the National Institute of Allergy and Infectious Diseases, tested several dosage strengths, including one with 10 million plaque-forming units (PFU).

They determined that a vaccine with 10 PFUs was just as effective as the highest dose tested (a dose which was still lower than the one currently in use in the DRC).

They vaccinated macaques 28 days prior to infecting them with a lethal dose of EBOV and then monitored the animals for 42 days after infection.

Even the macaques given the lowest dose appeared completely protected from disease due to EBOV.

The scientists say their study findings could help make more vaccine available for more people and may reduce adverse reactions to the vaccine because of the smaller amount of active ingredient.

Such reactions can include injection site irritation, headache, fatigue, fever, chills, myalgia, and arthralgia.

Demonstrating that the vaccine appears effective with adjusted dosing also could ease the burden on vaccine production.

The authors say that although results from preclinical and clinical studies can differ, these promising findings in macaques of complete protection with a lower-dose VSV-EBOV vaccine help support the possibility of similar clinical trials in people.


What to read next

Researchers unlock biomechanics of how Ebola virus attaches to its host cell
Ebola, very infectious but not very contagious disease
Existing anti-parasitic drug could offer treatment for Ebola